Study Outlines Real-World Efficacy of Duvelisib Plus Romidepsin in Patients With PTCL

Josie Ford, BS, a first-year medical student at the University of Connecticut and a member of the Salvia Jain Lab research team at Massachusetts General Hospital Cancer Center, shared real-world efficacy and safety data on duvelisib and romidepsin in patients with relapsed or refractory peripheral T-cell lymphoma and how the findings build on previous clinical trial research.